{
    "clinical_study": {
        "@rank": "60405", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose Drug-Drug Arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this arm will receive LY2456302 10.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)"
            }, 
            {
                "arm_group_label": "High Dose Drug-Drug Arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this arm will receive LY2456302 20.0 mg/day for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)"
            }, 
            {
                "arm_group_label": "Placebo/Low-Dose Drug Arm", 
                "arm_group_type": "Other", 
                "description": "Patients in this arm will receive placebo for 3 days (in Phase 1) and LY2456302 10.0 mg/day for 3 days (in Phase 2)"
            }, 
            {
                "arm_group_label": "Placebo/High-Dose Drug Arm", 
                "arm_group_type": "Other", 
                "description": "Patients in this arm will receive placebo for 3 days (in Phase 1) and LY2456302 20.0 mg/day for 3 days (in Phase 2)"
            }, 
            {
                "arm_group_label": "Placebo/Placebo Arm", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients in this arm will receive placebo for 3 days (in Phase 1) and for 3 subsequent days (in Phase 2)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is looking at the efficacy, rapidity, safety, and tolerability of two doses of\n      oral LY2456302 for treating patients with treatment resistant depression who are taking an\n      antidepressant that is not working for them."
        }, 
        "brief_title": "Proof-of-Concept Trial of LY2456302 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression", 
        "condition": "Treatment Resistant Depression", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, 18-65 years old.\n\n          -  Able to read, understand, and provide written, dated informed consent prior to\n             screening.\n\n          -  Diagnosed with Major Depressive Disorder (MDD), single or recurrent, and currently\n             experiencing a Major Depressive Episode (MDE) of at least eight weeks in duration,\n             prior to screening.\n\n          -  Has a history of TRD during the current MDE.\n\n          -  Meet the threshold on the total MADRS score of greater than or equal to 20 at both\n             screening and baseline visits (Day -5/-14 and Day 0), as confirmed by the remote\n             centralized MGH CTNI rater between the screen visit and the baseline visit.\n\n          -  In good general health\n\n          -  For female participants, status of non-childbearing potential or use of an acceptable\n             form of birth control\n\n          -  Body mass index between 18-35 kg/m2\n\n          -  Concurrent psychotherapy will be allowed if the type and frequency of the therapy has\n             been stable for at least three months prior to screening and is expected to remain\n             stable during participation in the study\n\n          -  Concurrent benzodiazepine and hypnotic therapy will be allowed if the therapy has\n             been stable for at least 4 weeks prior to screening and if it is expected to remain\n             stable during the course of the subject's participation in the study.\n\n        Exclusion Criteria:\n\n          -  Female of childbearing potential who is not willing to use one of the specified forms\n             of birth control during the study\n\n          -  Female that is pregnant or breastfeeding\n\n          -  Female with a positive pregnancy test at screening or baseline\n\n          -  History during the current MDE of failure to achieve a satisfactory response to >3\n             treatment courses of a therapeutic dose of an antidepressant therapy of at least 8\n             weeks duration during the current episode\n\n          -  Total MADRS score of <20 at the screen or baseline visits, or as assessed by the\n             remote, independent MGH CTNI rater and reported to the site\n\n          -  Current diagnosis of a Substance Use Disorder (Abuse or Dependence) with the\n             exception of nicotine dependence, at screening or within six months prior to\n             screening\n\n          -  Current diagnosis of Axis I disorders other than Dysthymic Disorder, Generalized\n             Anxiety Disorder, Social Anxiety Disorder, Panic Disorder or Specific Phobia (unless\n             one of these is comorbid and clinically unstable, and/or the focus of the\n             participant's treatment for the past 6 months or more)\n\n          -  History of bipolar disorder, schizophrenia or schizoaffective disorders, or any\n             history of psychotic symptoms in the current or previous depressive episodes\n\n          -  History of eating disorders within five years of screening\n\n          -  Any Axis I or Axis II Disorder, which at screening is clinically predominant to their\n             MDD or has been predominant at any time within 6 months prior to screening\n\n          -  Subject is considered at significant risk for suicidal behavior during the course of\n             their participation in the study\n\n          -  Subject has had electroconvulsive therapy in the current episode of depression\n\n          -  Has received vagus nerve stimulation (VNS) at any time prior to screening\n\n          -  Dementia, delirium, amnestic, or any other cognitive disorder\n\n          -  Has a clinically significant abnormality on the screening physical examination\n\n          -  Participation in any clinical trial with an investigational drug or device within the\n             past month or concurrent to study participation\n\n          -  Known history or current episode of: Uncontrolled hypertension, Recent myocardial\n             infarction (within one year) or a history of more than one myocardial infarction,\n             Syncopal event within the past year, Congestive heart failure, Angina pectoris,\n             Systolic BP <85 or >160 mmHg or diastolic BP >95 mmHg or heart rate <50 or >105 beats\n             per minute at screening or randomization, or QTcF greater than or equal to 450 msec\n             at screening or randomization.\n\n          -  Chronic lung disease\n\n          -  Lifetime history of surgical procedures involving the brain or meninges,\n             encephalitis, meningitis, degenerative central nervous system disorder, epilepsy,\n             mental retardation, or any other disease/procedure/accident/intervention associated\n             with significant injury to or malfunction of the central nervous system, or a history\n             of significant head trauma within the past 2 years\n\n          -  Presents with a history of Thyroid stimulating hormone outside of the normal limits\n             and clinically significant as determined by the investigator\n\n          -  Patients with diabetes mellitus fulfilling any of the following criteria:\n\n               1. Unstable diabetes mellitus defined as glycosylated hemoglobin (HbA1c) >8.5% at\n                  screening\n\n               2. Admitted to hospital for treatment of diabetes mellitus or diabetes mellitus\n                  related illness in the past 12 weeks\n\n               3. Not under physician care for diabetes mellitus\n\n               4. Has not been on the same dose of oral hypoglycaemic drug(s) and/or diet for the\n                  4 weeks prior to screening. For thiazolidinediones (glitazones) this period\n                  should not be less than 8 weeks.\n\n               5. Any other clinically significant abnormal laboratory result (as determined after\n                  evaluation by study investigator and MGH CTNI medical monitor) at the time of\n                  the screening exam.\n\n          -  History of hypothyroidism and has been on a stable dosage of thyroid replacement\n             medication, or was surgically treated less than six months prior to screening\n\n          -  History of hyperthyroidism which was treated (medically or surgically) less than six\n             months prior to screening\n\n          -  Any current or past history of any physical condition which in the investigator's\n             opinion might put the subject at risk or interfere with the interpretation of study\n             results\n\n          -  History of positive screening urine test for drugs of abuse\n\n          -  Patients with exclusionary laboratory values, or requiring treatment with\n             exclusionary concomitant medications, including tricyclic antidepressants and\n             monoamine oxidase inhibitors, or on two or more concomitant antidepressant therapies\n\n          -  Patients currently taking a proton pump inhibitor (PPI)/histamine 2 (H2) blocker or\n             with a history of chronic NSAID use\n\n          -  Patients with a positive test for Helicobacter pylori (urea breath test)\n\n          -  Patients with any of the following GI-related findings:\n\n               1. Clinically evident GI complaints or GI disease at Screening or Visit 1\n\n               2. Past history of gastric disease (including but not limited to peptic ulcer\n                  disease, gastritis (including atrophic gastritis), upper GI bleeding, any other\n                  GI precancerous conditions), and of any other clinically relevant GI disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "91", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01913535", 
            "org_study_id": "RAP-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low Dose Drug-Drug Arm", 
                "description": "Dose of LY2456302 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days)", 
                "intervention_name": "LY2456302", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High Dose Drug-Drug Arm", 
                "description": "Dose of LY2456302 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days)", 
                "intervention_name": "LY2456302", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo/Low-Dose Drug Arm", 
                "description": "For patients randomly assigned to the placebo/low-dose drug sequence, the dose of LY2456302 will be 10 mg/day during the second phase of the study (3 days)", 
                "intervention_name": "LY2456302", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo/High-Dose Drug Arm", 
                "description": "For patients randomly assigned to the placebo/high-dose drug sequence, the dose of LY2456302 will be 20 mg/day during the second phase of the study (3 days)", 
                "intervention_name": "LY2456302", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo/Placebo Arm", 
                "description": "For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days)", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antidepressive Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Depression", 
            "Treatment Resistant Depression"
        ], 
        "lastchanged_date": "July 30, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois"
                    }, 
                    "name": "Rush University"
                }, 
                "investigator": {
                    "last_name": "John Zajecka, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wichita", 
                        "country": "United States", 
                        "state": "Kansas"
                    }, 
                    "name": "University of Kansas"
                }, 
                "investigator": {
                    "last_name": "Sheldon H Preskorn, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27157"
                    }, 
                    "name": "Wake Forest University"
                }, 
                "investigator": {
                    "last_name": "James Kimball, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Temple University"
                }, 
                "investigator": {
                    "last_name": "Mary F Morrison, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Providence", 
                        "country": "United States", 
                        "state": "Rhode Island"
                    }, 
                    "name": "Brown University-Butler Hospital"
                }, 
                "investigator": {
                    "last_name": "Linda L Carpenter, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "5", 
        "official_title": "Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of LY2456302, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)", 
        "overall_contact": {
            "email": "mfava@partners.org", 
            "last_name": "Maurizio Fava, MD", 
            "phone": "617-724-0838"
        }, 
        "overall_contact_backup": {
            "email": "mflynn2@partners.org", 
            "last_name": "Martina Flynn", 
            "phone": "617-643-6028"
        }, 
        "overall_official": [
            {
                "affiliation": "Massachusetts General Hospital (Coordinating Center)", 
                "last_name": "Maurizio Fava, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Brown University-Butler Hospital", 
                "last_name": "Linda L Carpenter, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Rush University", 
                "last_name": "John Zajecka, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Temple University", 
                "last_name": "Mary F Morrison, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of Kansas", 
                "last_name": "Sheldon H Preskorn, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Wake Forest School of Medicine", 
                "last_name": "James Kimball, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This instrument is completed with a structured interview guide by the clinician based on his/her assessment of the patient's symptoms. This structured interview has been validated for use with time frames shorter than one week. The time frame for this scale is the past 48 hours.", 
            "measure": "Hamilton Rating Scale for Depression - 6 items", 
            "safety_issue": "No", 
            "time_frame": "Past 48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01913535"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Maurizio Fava, MD", 
            "investigator_title": "Overall Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Mental Health (NIMH)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Brown University-Butler Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Rush University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Temple University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Kansas", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Wake Forest School of Medicine", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}